Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-02

AUTHORS

Jinshan Shen, Robert Townsend, Xiaoli You, Yun Shen, Ping Zhan, Zexun Zhou, Dong Geng, Dianna Wu, Nadia McGirr, Kathleen Soucek, Elizabeth Proszynski, Janice Pursley, Eric Masson

ABSTRACT

BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies. RESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure. CONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies. More... »

PAGES

117-126

References to SciGraph publications

  • 2012-08. Time‐Varying Belatacept Exposure and Its Relationship to Efficacy/Safety Responses in Kidney‐Transplant Recipients in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2011-02. Oral Session II‐B (OII‐B) in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2010-05. CYP-Mediated Therapeutic Protein-Drug Interactions in CLINICAL PHARMACOKINETICS
  • 2009-09. Immunotherapy in Elderly Transplant Recipients in DRUGS & AGING
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2

    DOI

    http://dx.doi.org/10.1007/s40261-013-0153-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1050298806

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24217983


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Abatacept", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Area Under Curve", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "B7-2 Antigen", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase II as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials, Phase III as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Half-Life", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoconjugates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunosuppressive Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shen", 
            "givenName": "Jinshan", 
            "id": "sg:person.0646360451.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646360451.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Townsend", 
            "givenName": "Robert", 
            "id": "sg:person.01166761064.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166761064.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "You", 
            "givenName": "Xiaoli", 
            "id": "sg:person.01336302136.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336302136.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shen", 
            "givenName": "Yun", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhan", 
            "givenName": "Ping", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhou", 
            "givenName": "Zexun", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Geng", 
            "givenName": "Dong", 
            "id": "sg:person.0775237636.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775237636.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wu", 
            "givenName": "Dianna", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McGirr", 
            "givenName": "Nadia", 
            "id": "sg:person.01111466236.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111466236.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Soucek", 
            "givenName": "Kathleen", 
            "id": "sg:person.01157601436.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157601436.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Proszynski", 
            "givenName": "Elizabeth", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pursley", 
            "givenName": "Janice", 
            "id": "sg:person.0630643206.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630643206.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Bristol-Myers Squibb (United States)", 
              "id": "https://www.grid.ac/institutes/grid.419971.3", 
              "name": [
                "Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Masson", 
            "givenName": "Eric", 
            "id": "sg:person.014363567577.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2005.00749.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005387107"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2004.00332.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008106653"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3182007b95", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009438606"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1681/asn.2009111109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012075613"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1681/asn.2009111109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012075613"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e3181ff87cd", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012888147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1371/journal.pone.0026459", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016973491"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/tp.0b013e31819b5a58", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017865661"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.2012.84", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020898645", 
              "https://doi.org/10.1038/clpt.2012.84"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11319980-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022781285", 
              "https://doi.org/10.2165/11319980-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11319980-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022781285", 
              "https://doi.org/10.2165/11319980-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03016.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023223598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03016.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023223598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11316480-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025688462", 
              "https://doi.org/10.2165/11316480-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11316480-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025688462", 
              "https://doi.org/10.2165/11316480-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.2010.331", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026754692", 
              "https://doi.org/10.1038/clpt.2010.331"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/0091270007306958", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031261826"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2215/cjn.03791106", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031418032"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035491415"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2010.03338.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035491415"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmra033540", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041854653"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2009.03005.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051343043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/j.1600-6143.2009.03005.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051343043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa050085", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052307919"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa050085", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052307919"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4155/bio.10.54", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052956253"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4155/bio.12.79", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053687013"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-02", 
        "datePublishedReg": "2014-02-01", 
        "description": "BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept.\nMETHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies.\nRESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) \u03bcg/mL, and 13,587 (27%) and 21,241 (35%) \u03bcg\u00b7h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 \u03bcg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure.\nCONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s40261-013-0153-2", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1100199", 
            "issn": [
              "1173-2563", 
              "1179-1918"
            ], 
            "name": "Clinical Drug Investigation", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "34"
          }
        ], 
        "name": "Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients", 
        "pagination": "117-126", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "ef9bc3a1091751c77f1ed53a199e732255a92367ec320256281417411c56aa02"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24217983"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "9504817"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40261-013-0153-2"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1050298806"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40261-013-0153-2", 
          "https://app.dimensions.ai/details/publication/pub.1050298806"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T09:57", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89807_00000002.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs40261-013-0153-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-013-0153-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    268 TRIPLES      21 PREDICATES      63 URIs      35 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40261-013-0153-2 schema:about N01e8e9274686452f896bb295b91d3121
    2 N06eef45a2f2b44beaebd18a15e83028a
    3 N0fe5481219e844f780c85b4b07ce7c91
    4 N2372a47532b44f8e9a795a2d1616583a
    5 N288c0fb557c74696a15baeec0b7d3b8e
    6 N4d0ff92d516c4668ad9fb858e54759ec
    7 N51525abb87fa4398b2d8ab637da9a0f9
    8 N52984685f32643658be83b74fec2c8b4
    9 N7b56821fdd6d4ac28e01f4ae30d9c9aa
    10 N7d42169489d14e87b492201b10630da6
    11 N9af6022eaed14a7eaf691ea003cc4b5b
    12 Na7b3a0f15f7d4bcfb69f2ea807ce4787
    13 Nd11e07edc3a547ecb33d4c6b6b736f1c
    14 Nf6b1d79551e24ea3a3a8d1c31097710b
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N75867fdc46c848da96c5a877e4157a6e
    18 schema:citation sg:pub.10.1038/clpt.2010.331
    19 sg:pub.10.1038/clpt.2012.84
    20 sg:pub.10.2165/11316480-000000000-00000
    21 sg:pub.10.2165/11319980-000000000-00000
    22 https://doi.org/10.1056/nejmoa050085
    23 https://doi.org/10.1056/nejmra033540
    24 https://doi.org/10.1097/tp.0b013e31819b5a58
    25 https://doi.org/10.1097/tp.0b013e3181ff87cd
    26 https://doi.org/10.1097/tp.0b013e3182007b95
    27 https://doi.org/10.1111/j.1600-6143.2004.00332.x
    28 https://doi.org/10.1111/j.1600-6143.2005.00749.x
    29 https://doi.org/10.1111/j.1600-6143.2009.03005.x
    30 https://doi.org/10.1111/j.1600-6143.2010.03016.x
    31 https://doi.org/10.1111/j.1600-6143.2010.03338.x
    32 https://doi.org/10.1177/0091270007306958
    33 https://doi.org/10.1371/journal.pone.0026459
    34 https://doi.org/10.1681/asn.2009111109
    35 https://doi.org/10.2215/cjn.03791106
    36 https://doi.org/10.4155/bio.10.54
    37 https://doi.org/10.4155/bio.12.79
    38 schema:datePublished 2014-02
    39 schema:datePublishedReg 2014-02-01
    40 schema:description BACKGROUND AND OBJECTIVES: Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. METHODS: The pharmacokinetics, pharmacodynamics (CD86 receptor occupancy), and immunogenicity of belatacept were studied in de novo adult kidney transplant recipients in phase II and III clinical studies. RESULTS: Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively. The median belatacept elimination half-life was 8-9 days. Belatacept exhibited concentration-dependent binding to CD86 receptors. The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period. The cumulative incidence of developing anti-belatacept antibodies was 5.3% up to 3 years post-transplant and had no impact on belatacept exposure. CONCLUSIONS: Belatacept in adult kidney transplant demonstrated linear pharmacokinetics with low variability, concentration-dependent pharmacodynamics, and a low incidence of anti-drug antibodies.
    41 schema:genre research_article
    42 schema:inLanguage en
    43 schema:isAccessibleForFree true
    44 schema:isPartOf N2f8aec38445e45ce8df9c6e1a3a15335
    45 Nf25ba868526541598436e3eb1e9fb43c
    46 sg:journal.1100199
    47 schema:name Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
    48 schema:pagination 117-126
    49 schema:productId N2964b5c1a4964f9a9fa7291c1b26df57
    50 N5db7e1e4410c4043848e454583c4e4b8
    51 N7ddd2f6944f54ef4bd8ae31a28444cc0
    52 N9fcf61e8a46a418694a30912e53d865a
    53 Nd40a9484ce7f49a2bddd9da88c799f0a
    54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050298806
    55 https://doi.org/10.1007/s40261-013-0153-2
    56 schema:sdDatePublished 2019-04-11T09:57
    57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    58 schema:sdPublisher N4247ff6f8619493faae66a3c6dbf026e
    59 schema:url http://link.springer.com/10.1007%2Fs40261-013-0153-2
    60 sgo:license sg:explorer/license/
    61 sgo:sdDataset articles
    62 rdf:type schema:ScholarlyArticle
    63 N01e8e9274686452f896bb295b91d3121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    64 schema:name Antibodies
    65 rdf:type schema:DefinedTerm
    66 N06eef45a2f2b44beaebd18a15e83028a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    67 schema:name Adult
    68 rdf:type schema:DefinedTerm
    69 N086901e6d1ef4a4fa627c2e72e32a320 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    70 schema:familyName Wu
    71 schema:givenName Dianna
    72 rdf:type schema:Person
    73 N0fe5481219e844f780c85b4b07ce7c91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    74 schema:name Time Factors
    75 rdf:type schema:DefinedTerm
    76 N2372a47532b44f8e9a795a2d1616583a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    77 schema:name Immunosuppressive Agents
    78 rdf:type schema:DefinedTerm
    79 N288c0fb557c74696a15baeec0b7d3b8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    80 schema:name Half-Life
    81 rdf:type schema:DefinedTerm
    82 N2964b5c1a4964f9a9fa7291c1b26df57 schema:name doi
    83 schema:value 10.1007/s40261-013-0153-2
    84 rdf:type schema:PropertyValue
    85 N2f7cccaf574a44df951e628c4e4ec548 rdf:first N9479b7c6d57d4432bd3410385dab337e
    86 rdf:rest N75afa44cf928438fa2a82894da1f3cc2
    87 N2f8aec38445e45ce8df9c6e1a3a15335 schema:volumeNumber 34
    88 rdf:type schema:PublicationVolume
    89 N3858646383ab4933a6ef93a75a6e49b7 rdf:first sg:person.01111466236.19
    90 rdf:rest Ndea4612db8f54187b9cec9e1a2d15bba
    91 N3b522cd14a07430692faf224c9223e56 rdf:first sg:person.014363567577.38
    92 rdf:rest rdf:nil
    93 N3bcad6916e864010a4419439f6ced6c6 rdf:first N5e1e31ef422245698db4e36292cd5e9f
    94 rdf:rest Nd4318dfe196b471097f90ad69a25d15f
    95 N4247ff6f8619493faae66a3c6dbf026e schema:name Springer Nature - SN SciGraph project
    96 rdf:type schema:Organization
    97 N4d0ff92d516c4668ad9fb858e54759ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Kidney Transplantation
    99 rdf:type schema:DefinedTerm
    100 N51525abb87fa4398b2d8ab637da9a0f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name B7-2 Antigen
    102 rdf:type schema:DefinedTerm
    103 N52984685f32643658be83b74fec2c8b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Humans
    105 rdf:type schema:DefinedTerm
    106 N5db7e1e4410c4043848e454583c4e4b8 schema:name nlm_unique_id
    107 schema:value 9504817
    108 rdf:type schema:PropertyValue
    109 N5e1e31ef422245698db4e36292cd5e9f schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    110 schema:familyName Shen
    111 schema:givenName Yun
    112 rdf:type schema:Person
    113 N75867fdc46c848da96c5a877e4157a6e rdf:first sg:person.0646360451.54
    114 rdf:rest Nb60ec0f1ce9a436ebd5b3a6de1f044e5
    115 N75afa44cf928438fa2a82894da1f3cc2 rdf:first sg:person.0630643206.07
    116 rdf:rest N3b522cd14a07430692faf224c9223e56
    117 N7b56821fdd6d4ac28e01f4ae30d9c9aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Abatacept
    119 rdf:type schema:DefinedTerm
    120 N7d42169489d14e87b492201b10630da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Area Under Curve
    122 rdf:type schema:DefinedTerm
    123 N7ddd2f6944f54ef4bd8ae31a28444cc0 schema:name readcube_id
    124 schema:value ef9bc3a1091751c77f1ed53a199e732255a92367ec320256281417411c56aa02
    125 rdf:type schema:PropertyValue
    126 N8b90aa44e721472aa663718038aacb40 rdf:first Nb83ec62aaf8d4b35941856df481ced6f
    127 rdf:rest Na599928886e744e8870535b97936f01b
    128 N9479b7c6d57d4432bd3410385dab337e schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    129 schema:familyName Proszynski
    130 schema:givenName Elizabeth
    131 rdf:type schema:Person
    132 N9af6022eaed14a7eaf691ea003cc4b5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Clinical Trials, Phase II as Topic
    134 rdf:type schema:DefinedTerm
    135 N9fcf61e8a46a418694a30912e53d865a schema:name pubmed_id
    136 schema:value 24217983
    137 rdf:type schema:PropertyValue
    138 Na599928886e744e8870535b97936f01b rdf:first sg:person.0775237636.64
    139 rdf:rest Ncc4d3c7a7fda480590e2525274712fdb
    140 Na67f059cc248488e92b71bbf654b47b0 rdf:first sg:person.01336302136.32
    141 rdf:rest N3bcad6916e864010a4419439f6ced6c6
    142 Na7b3a0f15f7d4bcfb69f2ea807ce4787 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Immunoconjugates
    144 rdf:type schema:DefinedTerm
    145 Nb60ec0f1ce9a436ebd5b3a6de1f044e5 rdf:first sg:person.01166761064.07
    146 rdf:rest Na67f059cc248488e92b71bbf654b47b0
    147 Nb83ec62aaf8d4b35941856df481ced6f schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    148 schema:familyName Zhou
    149 schema:givenName Zexun
    150 rdf:type schema:Person
    151 Ncc4d3c7a7fda480590e2525274712fdb rdf:first N086901e6d1ef4a4fa627c2e72e32a320
    152 rdf:rest N3858646383ab4933a6ef93a75a6e49b7
    153 Nd11e07edc3a547ecb33d4c6b6b736f1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Dose-Response Relationship, Drug
    155 rdf:type schema:DefinedTerm
    156 Nd40a9484ce7f49a2bddd9da88c799f0a schema:name dimensions_id
    157 schema:value pub.1050298806
    158 rdf:type schema:PropertyValue
    159 Nd4318dfe196b471097f90ad69a25d15f rdf:first Nebf767d85b4e41c6a0283b07f32097d8
    160 rdf:rest N8b90aa44e721472aa663718038aacb40
    161 Ndea4612db8f54187b9cec9e1a2d15bba rdf:first sg:person.01157601436.77
    162 rdf:rest N2f7cccaf574a44df951e628c4e4ec548
    163 Nebf767d85b4e41c6a0283b07f32097d8 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    164 schema:familyName Zhan
    165 schema:givenName Ping
    166 rdf:type schema:Person
    167 Nf25ba868526541598436e3eb1e9fb43c schema:issueNumber 2
    168 rdf:type schema:PublicationIssue
    169 Nf6b1d79551e24ea3a3a8d1c31097710b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Clinical Trials, Phase III as Topic
    171 rdf:type schema:DefinedTerm
    172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Medical and Health Sciences
    174 rdf:type schema:DefinedTerm
    175 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Clinical Sciences
    177 rdf:type schema:DefinedTerm
    178 sg:journal.1100199 schema:issn 1173-2563
    179 1179-1918
    180 schema:name Clinical Drug Investigation
    181 rdf:type schema:Periodical
    182 sg:person.01111466236.19 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    183 schema:familyName McGirr
    184 schema:givenName Nadia
    185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111466236.19
    186 rdf:type schema:Person
    187 sg:person.01157601436.77 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    188 schema:familyName Soucek
    189 schema:givenName Kathleen
    190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157601436.77
    191 rdf:type schema:Person
    192 sg:person.01166761064.07 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    193 schema:familyName Townsend
    194 schema:givenName Robert
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166761064.07
    196 rdf:type schema:Person
    197 sg:person.01336302136.32 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    198 schema:familyName You
    199 schema:givenName Xiaoli
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336302136.32
    201 rdf:type schema:Person
    202 sg:person.014363567577.38 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    203 schema:familyName Masson
    204 schema:givenName Eric
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014363567577.38
    206 rdf:type schema:Person
    207 sg:person.0630643206.07 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    208 schema:familyName Pursley
    209 schema:givenName Janice
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630643206.07
    211 rdf:type schema:Person
    212 sg:person.0646360451.54 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    213 schema:familyName Shen
    214 schema:givenName Jinshan
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646360451.54
    216 rdf:type schema:Person
    217 sg:person.0775237636.64 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
    218 schema:familyName Geng
    219 schema:givenName Dong
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775237636.64
    221 rdf:type schema:Person
    222 sg:pub.10.1038/clpt.2010.331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026754692
    223 https://doi.org/10.1038/clpt.2010.331
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1038/clpt.2012.84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020898645
    226 https://doi.org/10.1038/clpt.2012.84
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.2165/11316480-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025688462
    229 https://doi.org/10.2165/11316480-000000000-00000
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.2165/11319980-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022781285
    232 https://doi.org/10.2165/11319980-000000000-00000
    233 rdf:type schema:CreativeWork
    234 https://doi.org/10.1056/nejmoa050085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052307919
    235 rdf:type schema:CreativeWork
    236 https://doi.org/10.1056/nejmra033540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041854653
    237 rdf:type schema:CreativeWork
    238 https://doi.org/10.1097/tp.0b013e31819b5a58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017865661
    239 rdf:type schema:CreativeWork
    240 https://doi.org/10.1097/tp.0b013e3181ff87cd schema:sameAs https://app.dimensions.ai/details/publication/pub.1012888147
    241 rdf:type schema:CreativeWork
    242 https://doi.org/10.1097/tp.0b013e3182007b95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009438606
    243 rdf:type schema:CreativeWork
    244 https://doi.org/10.1111/j.1600-6143.2004.00332.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008106653
    245 rdf:type schema:CreativeWork
    246 https://doi.org/10.1111/j.1600-6143.2005.00749.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1005387107
    247 rdf:type schema:CreativeWork
    248 https://doi.org/10.1111/j.1600-6143.2009.03005.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051343043
    249 rdf:type schema:CreativeWork
    250 https://doi.org/10.1111/j.1600-6143.2010.03016.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023223598
    251 rdf:type schema:CreativeWork
    252 https://doi.org/10.1111/j.1600-6143.2010.03338.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035491415
    253 rdf:type schema:CreativeWork
    254 https://doi.org/10.1177/0091270007306958 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031261826
    255 rdf:type schema:CreativeWork
    256 https://doi.org/10.1371/journal.pone.0026459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016973491
    257 rdf:type schema:CreativeWork
    258 https://doi.org/10.1681/asn.2009111109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012075613
    259 rdf:type schema:CreativeWork
    260 https://doi.org/10.2215/cjn.03791106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031418032
    261 rdf:type schema:CreativeWork
    262 https://doi.org/10.4155/bio.10.54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052956253
    263 rdf:type schema:CreativeWork
    264 https://doi.org/10.4155/bio.12.79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053687013
    265 rdf:type schema:CreativeWork
    266 https://www.grid.ac/institutes/grid.419971.3 schema:alternateName Bristol-Myers Squibb (United States)
    267 schema:name Clinical Pharmacology and Pharmacometrics, Oncology-Immunology, Bristol-Myers Squibb, P.O. Box 4000, E1.409, Princeton, NJ 08543-4000, USA
    268 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...